Get the Finder app 🥳

Track your credit score, free

Free

How to buy Johnson And Johnson shares

Own Johnson And Johnson shares in just a few minutes.

Updated

Fact checked

Johnson & Johnson is a drug manufacturers—general business with stocks listed in the US. Johnson And Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars.

How to buy shares in Johnson And Johnson

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Johnson And Johnson. Find the share by name or ticker symbol: JNJ. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Johnson And Johnson reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Johnson And Johnson, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Johnson And Johnson. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Johnson And Johnson share price

Use our graph to track the performance of JNJ stocks over time.

Johnson And Johnson shares at a glance

Information last updated 2020-09-25.
52-week rangeUSD$109.16 - USD$157
50-day moving average USD$149.3292
200-day moving average USD$144.5778
Target priceUSD$165.06
PE ratio 25.3849
Dividend yield USD$4.04 (2.8%)
Earnings per share (TTM) USD$5.684

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

  • $0 brokerage for US stocks
  • Trades starting from $50
  • Fractional shares
  • Copy top traders
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

Is it a good time to buy Johnson And Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Johnson And Johnson under- or over-valued?

Valuing Johnson And Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson And Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson And Johnson's P/E ratio

Johnson And Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson And Johnson shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Johnson And Johnson's PEG ratio

Johnson And Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.126. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson And Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Johnson And Johnson's EBITDA

Johnson And Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$27.2 billion.

The EBITDA is a measure of a Johnson And Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson And Johnson financials

Revenue TTM US$80.5 billion
Operating margin TTM 25.09%
Gross profit TTM US$54.6 billion
Return on assets TTM 8.05%
Return on equity TTM 24.54%
Profit margin 18.86%
Book value 23.924
Market capitalisation US$391.8 billion

TTM: trailing 12 months

Shorting Johnson And Johnson shares

There are currently 10.6 million Johnson And Johnson shares held short by investors – that's known as Johnson And Johnson's "short interest". This figure is 14.8% down from 12.4 million last month.

There are a few different ways that this level of interest in shorting Johnson And Johnson shares can be evaluated.

Johnson And Johnson's "short interest ratio" (SIR)

Johnson And Johnson's "short interest ratio" (SIR) is the quantity of Johnson And Johnson shares currently shorted divided by the average quantity of Johnson And Johnson shares traded daily (recently around 5.4 million). Johnson And Johnson's SIR currently stands at 1.96. In other words for every 100,000 Johnson And Johnson shares traded daily on the market, roughly 1960 shares are currently held short.

However Johnson And Johnson's short interest can also be evaluated against the total number of Johnson And Johnson shares, or, against the total number of tradable Johnson And Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson And Johnson's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Johnson And Johnson shares in existence, roughly 0 shares are currently held short) or 0.004% of the tradable shares (for every 100,000 tradable Johnson And Johnson shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson And Johnson.

Find out more about how you can short Johnson And Johnson stock.

Johnson And Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson And Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson And Johnson's total ESG risk score

Total ESG risk: 35.78

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson And Johnson's overall score of 35.78 (as at 07/31/2020) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson And Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson And Johnson's environmental score

Environmental score: 3.79/100

Johnson And Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson And Johnson's social score

Social score: 25.14/100

Johnson And Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson And Johnson's governance score

Governance score: 15.85/100

Johnson And Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson And Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson And Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson And Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson And Johnson has a damaged public profile.

Environmental, social, and governance (ESG) summary

Johnson & Johnson was last rated for ESG on: 2020-08-01.

Total ESG score 35.78
Total ESG percentile 72.34
Environmental score 3.79
Environmental score percentile 7
Social score 25.14
Social score percentile 7
Governance score 15.85
Governance score percentile 7
Level of controversy 4

Johnson And Johnson share dividends

68%

Dividend payout ratio: 67.84% of net profits

Recently Johnson And Johnson has paid out, on average, around 67.84% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.8% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson And Johnson shareholders could enjoy a 2.8% return on their shares, in the form of dividend payments. In Johnson And Johnson's case, that would currently equate to about $4.04 per share.

Johnson And Johnson's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Johnson And Johnson's most recent dividend payout was on 7 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 23 August 2020 (the "ex-dividend date").

Have Johnson And Johnson's shares ever split?

Johnson And Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson And Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson And Johnson shares which in turn could have impacted Johnson And Johnson's share price.

Johnson And Johnson share price volatility

Over the last 12 months, Johnson And Johnson's shares have ranged in value from as little as US$109.16 up to US$157. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson And Johnson's is 0.6817. This would suggest that Johnson And Johnson's shares are less volatile than average (for this exchange).

Johnson And Johnson overview

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site